<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug dosing for the treatment of drug-susceptible tuberculosis in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug dosing for the treatment of drug-susceptible tuberculosis in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drug dosing for the treatment of drug-susceptible tuberculosis in children</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Drugs</td> <td class="subtitle1">Dosage forms (oral)</td> <td class="subtitle1">Daily dosage (range; mg/kg)</td> <td class="subtitle1">Maximum daily dose</td> <td class="subtitle1">Adverse reactions</td> </tr> <tr> <td>Ethambutol</td> <td>Tablets: <ul class="decimal_heading"> <li>100 mg</li> <li>400 mg (scored)</li> </ul> <p class="extra_spacing_top">Tablets may be crushed and given with food</p> </td> <td>20 (15 to 25)</td> <td>1 g</td> <td>Optic neuritis (usually reversible), decreased red-green color discrimination, gastrointestinal tract disturbances, hypersensitivity</td> </tr> <tr> <td>Isoniazid*</td> <td>Scored tablets: <ul class="decimal_heading"> <li>100 mg</li> <li>300 mg</li> <li>50 mg/mL syrup</li> </ul> <p class="extra_spacing_top">Tablets may be crushed and given with food</p> </td> <td>10 (10 to 15)</td> <td>300 mg</td> <td> <p>Mild hepatic enzyme elevation, hepatitis (increased in combination with rifampin), peripheral neuropathy, hypersensitivity</p> Given with pyridoxine to persons at risk of or with peripheral neuropathy; for moxifloxacin-rifapentine based regimen, all patients received pyridoxine<sup>[1]</sup></td> </tr> <tr> <td>Pyrazinamide*</td> <td>Scored tablets:<sup>¶</sup> <ul class="decimal_heading"> <li>500 mg</li> </ul> </td> <td>35 (30 to 40)</td> <td>2 g</td> <td>Hepatotoxic effects, hyperuricemia, arthralgia, gastrointestinal tract upset, pruritus, rash</td> </tr> <tr> <td>Rifampin (rifampicin)*</td> <td>Capsules:<sup>¶</sup> <ul class="decimal_heading"> <li>150 mg</li> <li>300 mg</li> </ul> </td> <td>15 to 20<sup>Δ</sup></td> <td>600 mg</td> <td>Orange discoloration of secretions or urine, staining of contact lenses, vomiting, hepatitis, influenza-like reaction, thrombocytopenia, pruritus; oral contraceptives may be ineffective</td> </tr> <tr> <td>Rifapentine<sup>◊</sup><sup>[1]</sup></td> <td>Tablets: <ul class="decimal_heading"> <li>150 mg</li> </ul> <p class="extra_spacing_top">Tablets may be crushed and given with food</p> </td> <td>1200 mg (weight over 40 kg, age ≥12 years)</td> <td>1200 mg</td> <td>Orange discoloration of secretions or urine, staining of contact lenses, headache, vomiting, hepatitis, hyperbilirubinemia, influenza-like reaction, anemia, lymphopenia, pruritus; oral contraceptives may be ineffective</td> </tr> <tr> <td>Moxifloxacin<sup>◊</sup><sup>[1]</sup></td> <td>Tablets: <ul class="decimal_heading"> <li>400 mg</li> </ul> </td> <td>400 mg (weight over 40 kg, age ≥12 years)</td> <td>400 mg</td> <td>Tendinopathy, gastrointestinal tract disturbances, cardiac disturbances, peripheral neuropathy, rash, headache, restlessness, confusion; can prolong QTc interval, hypersensitivity reactions, theoretical effect on growing cartilage</td> </tr> </tbody></table></div><div class="graphic_lgnd">For approach to selecting combination regimen and duration of initiation and continuation phases of treatment, refer to clinical topic. For additional dosing guidance for children weighing &gt;40 kg or &gt;15 years of age, including doses rounded to available pill strengths, refer to the Lexicomp drug monographs included within UpToDate.</div><div class="graphic_footnotes"><p>* Combination formulations are available in some areas outside the United States containing various strengths of rifampin, isoniazid, and/or pyrazinamide; confirm local product labeling before use. Isoniazid and rifampin also are available for parenteral administration.</p>
<p>¶ An oral suspension may be prepared by a compounding pharmacy.</p>
<p>Δ Many experts recommend using a daily rifampin dose of 20 to 30 mg/kg/day for infants and toddlers and for serious forms of tuberculosis such as meningitis and disseminated disease.</p>
◊ For details of rifapentine-moxifloxacin-based 4-month regimen, refer to separately available table in UpToDate.</div><div class="graphic_reference">Reference:
<ol>
<li>Carr W, Kurbatova E, Starks A, et al. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 7:285.</li>
</ol>
<p class="extra_spacing_top">Adapted from: Tuberculosis. In: Red Book: 2021 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics 2021.</p></div><div id="graphicVersion">Graphic 79897 Version 29.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
